Research Article
Is it possible to improve antioxidant activity of curcumin with the structure of lipid- based nanocarriers?
Abstract
Although curcumin is a commonly used antioxidant in cosmetic and pharmaceutical products, the dermal
efficacy of curcumin is limited due to its very low solubility and poor permeability. Considering dermal application,
lipid-based nanocarriers (LbNs) are highlighted as promising delivery systems for enhancing the efficacy of active
substances. The aim of this study is to evaluate the effect of the components of LbNs on the antioxidant activity of
curcumin. For this purpose, the mixture of Precirol® ATO5 and Tristearin was selected as solid lipid; while vitamin E,
pomegranate seed oil (PSO) and Labrafac® Lipophile WL 1349 were used as liquid lipids. Solid lipid nanoparticles
(SLN), nanostructured lipid carriers (NLC) and nanoemulsion (NE) formulations were designed by using different
combination of these lipids and Gelucire®50/13 as an amphiphilic surfactant. The particle size, PDI, zeta potential
analysis, encapsulation efficiency and in-vitro release studies were performed as particle characteristics. The
contribution of LbNs with different structures to the antioxidant capacity of curcumin was evaluated by in-vitro ABTS
scavenging experiment. While SLN has an average particle size of 106.7 nm with negative zeta potential, the size of
NLC and NE formulations were below 100nm. The highest curcumin release upon 24h was obtained by NLC
formulation prepared with PSO. A significant contribution to the antioxidant activity of curcumin was obtained when
vitamin E and PSO were used as liquid lipid in NLC and NE formulations. In conclusion, it is possible to improve the
antioxidant effect of curcumin by the modification of the structure of LbNs.
Keywords
Lipid-based nanocarriers Solid lipid nanoparticles Nanostructured lipid carriers Nanoemulsions Curcumin Antioxidant effect
References
- Tsai CF, Hsieh TH, Lee JN, Hsu CY, Wang YC, Kuo KK, Kuo PL. Curcumin suppresses phthalate-induced metastasis and the proportion of cancer stem cell (CSC)-like cells via the inhibition of AhR/ERK/SK1 signaling in hepatocellular carcinoma. J Agric Food Chem. 2015; 63(48): 10388-10398. [CrossRef]
- Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. 2007; 105-125. [CrossRef]
- Ghalandarlaki N, Alizadeh AM, Ashkani-Esfahani S. Nanotechnology-applied curcumin for different diseases therapy. BioMed Research International, 2014. [CrossRef]
- Wang L, Zhang B, Huang F, Liu B, Xie Y. Curcumin inhibits lipolysis via suppression of ER stress in adipose tissue and prevents hepatic insulin resistances. J Lipid Res. 2016; 57(7): 1243-1255. [CrossRef]
- Wu R, Wang L, Yin R, Hudlikar R, Li S, Kuo HCD, Kong AN. Epigenetics/epigenomics and prevention by curcumin of early stages of inflammatory‐driven colon cancer. Mol Carcinog. 2020; 59(2): 227-236. [CrossRef]
- Li H, Sureda A, Devkota HP, Pittalà V, Barreca D, Silva AS, Nabavi SM. Curcumin, the golden spice in treating cardiovascular diseases. Biotechnol Adv 2020; 38: 107343. [CrossRef]
- Liochev SI. Reactive oxygen species and the free radical theory of aging. Free Radic Biol Med. 2013; 60: 1-4. [CrossRef]
- Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, Bitto A. Oxidative stress: harms and benefits for human health. Oxid Med Cell Longev. 2017. [CrossRef]
- Brainina K, Stozhko N, Vidrevich M. Antioxidants: Terminology, methods, and future considerations. Antioxidants. 2019; 8(8): 297. [CrossRef]
- Heger M, van Golen RF, Broekgaarden M, Michel MC. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancers. Pharmacol Rev. 2014; 66(1): 222–307. [CrossRef]
- Fadus MC, Lau C, Bikhchandani J, Lynch HT. Curcumin: An age-old anti-inflammatory and anti-neoplastic agent. J Tradit Complement Med. 2017; 7(3): 339-346. [CrossRef]
- Panahi Y, Fazlolahzadeh O, Atkin SL, Majeed M, Butler AE, Johnston TP, Sahebkar A. Evidence of curcumin and curcumin analogue effects in skin diseases: A narrative review. J Cell Physiol. 2019; 234(2): 1165-1178. [CrossRef]
- Lin X, Shi Y, Yu S, Li S, Li W, Li M, Cong M. Preparation of poloxamer188-b-PCL and study on in vitro radioprotection activity of curcumin-loaded nanoparticles. Front Chem 2020; 8: 212. [CrossRef]
- Dario MF, Oliveira FF, Marins DS, Baby AR, Velasco MV, Löbenberg R, Bou-Chacra NA. Synergistic photoprotective activity of nanocarrier containing oil of Acrocomia aculeata (Jacq.) Lodd. Ex. Martius—Arecaceae. Ind Crops Prod. 2018; 112: 305-312. [CrossRef]
- Teixeira MI, Lopes CM, Amaral MH, Costa PC. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. Eur J Pharm Biopharm. 2020; 149: 192-217. [CrossRef]
- Rai VK, Mishra N, Yadav KS, Yadav NP. Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: formulation development, stability issues, basic considerations and applications. J Control Release. 2018; 270: 203-225. [CrossRef]
- Ashaolu TJ. (2021). Nanoemulsions for health, food, and cosmetics: A review. Environ Chem Lett. 2021; 19(4): 3381- 3395. [CrossRef]
- Abu‐Huwaij R, Al‐Assaf SF, Hamed R. Recent exploration of nanoemulsions for drugs and cosmeceuticals delivery. J Cosmet Dermatol. 2021. [CrossRef]
- Costa CP, Moreira JN, Lobo JMS, Silva AC. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies. Acta Pharm Sin B. 2021; 11(4): 925-940. [CrossRef]
- Tehranifar A, Selahvarzi Y, Kharrazi M, Bakhsh VJ. High potential of agro-industrial by-products of pomegranate (Punica granatum L.) as the powerful antifungal and antioxidant substances. Ind Crops Prod. 2011; 34(3): 1523-1527. [CrossRef]
- Cao Y, Wang L, He M, Zhang Y, Wang H. Nanodispersions of monoglycerides of punicic acid: a potential nutrient precursor with higher oxidative stability and cytotoxicity. RSC Advances. 2014; 4(82): 43392-43398. [CrossRef]
- Keskin Çavdar H, Koçak Yanık D, Gök U, Göğüş F. Optimisation of microwave-assisted extraction of pomegranate (Punica granatum L.) seed oil and evaluation of its physicochemical and bioactive properties. Food Technol Biotechnol. 2017; 55(1): 86-94. [CrossRef]
- Nachbar F, Korting HC. The role of vitamin E in normal and damaged skin. J Mol Med. 1995; 73(1): 7-17. [CrossRef]
- Schneider C, Gordon ON, Edwards RL, Luis PB. Degradation of curcumin: from mechanism to biological implications. J Agric Food Chem. 2015; 63(35): 7606-7614. [CrossRef]
- Kharat M, Du Z, Zhang G, McClements DJ. Physical and chemical stability of curcumin in aqueous solutions and emulsions: Impact of pH, temperature, and molecular environment J Agric Food Chem. 2017; 65(8): 1525-1532. [CrossRef]
- Zoubari G, Staufenbiel S, Volz P, Alexiev U, Bodmeier R. Effect of drug solubility and lipid carrier on drug release from lipid nanoparticles for dermal delivery. Eur J Pharm Biopharm. 2017; 110: 39-46. [CrossRef]
- Panigrahi KC, Patra CN, Jena GK, Ghose D, Jena J, Panda SK, Sahu M. Gelucire: A versatile polymer for modified release drug delivery system. Future J Pharm Sci. 2018; 4(1): 102-108. [CrossRef]
- Tsai MJ, Wu PC, Huang YB, Chang JS, Lin CL, Tsai YH, Fang JY. Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int J Pharm. 2012; 423(2): 461-470. [CrossRef]
- Shimpi SL, Mahadik KR, Paradkar AR. Study on mechanism for amorphous drug stabilization using Gelucire 50/13. Chem Pharm Bull 2009; 57(9): 937-942. [CrossRef]
- Fini A, Moyano JR, Ginés JM, Perez-Martinez JI, Rabasco AM. Diclofenac salts, II. Solid dispersions in PEG6000 and Gelucire 50/13. Eur J Pharm Biopharm. 2005; 60(1): 99-111. [CrossRef]
- Singh SK, Verma PRP, Razdan B. Development and characterization of a lovastatin-loaded self-microemulsifying drug delivery system. Pharm Dev Technol. 2010; 15(5): 469-483. [CrossRef]
- Qi S, Marchaud D, Craig DQ. An investigation into the mechanism of dissolution rate enhancement of poorly water- soluble drugs from spray chilled gelucire 50/13 microspheres. J Pharm Sci. 2010; 99(1): 262-274. [CrossRef]
- de Oliveira Eloy J, Saraiva J, de Albuquerque S, Marchetti JM. Solid dispersion of ursolic acid in Gelucire 50/13: a strategy to enhance drug release and trypanocidal activity. AAPS PharmSciTech. 2012; 13(4): 1436-1445. [CrossRef]
- Date AA, Vador N, Jagtap A, Nagarsenker MS. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery. Nanotechnology. 2011; 22(27): 275102. [CrossRef]
- Obeidat WM, Schwabe K, Müller RH, Keck CM. Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2010; 76(1): 56-67. [CrossRef]
- Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharmscitech. 2011; 12(1): 62-76. [CrossRef]
- Babick F. Dynamic light scattering (DLS). In: Vasile-Dan H, Wolfgang E.S. U, Alexander G. S. (Eds). Characterization of Nanoparticles. Elseviser, 2020, pp. 137-172. [CrossRef]
- [38] Mehnert W, Mäder K. (2012). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2012; 64: 83-101. [CrossRef]
- Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, Ricci M. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm. 2008; 357(1-2): 295-304. [CrossRef]
- Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PN, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release. 2010; 144(2): 233-241. [CrossRef]
- Khalil RM, Abd-Elbary A, Kassem MA, Ghorab MM, Basha M. Nanostructured lipid carriers (NLCs) versus solid lipid nanoparticles (SLNs) for topical delivery of meloxicam. Pharm Dev Technol. 2014; 19(3): 304-314. [CrossRef]
- Bhaskar K, Anbu J, Ravichandiran V, Venkateswarlu V, Rao YM. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis. 2009; 8(1): 1-15. [CrossRef]
- Homayouni A, Amini M, Sohrabi M, Varshosaz J, Nokhodchi A. Curcumin nanoparticles containing poloxamer or soluplus tailored by high pressure homogenization using antisolvent crystallization. Int J Pharm. 2019; 562: 124-134. [CrossRef]
- Waghule T, Rapalli VK, Singhvi G, Manchanda, P, Hans, N, Dubey, SK, Nayak AK. Voriconazole loaded nanostructured lipid carriers based topical delivery system: QbD based designing, characterization, in-vitro and ex- vivo evaluation. J Drug Deliv Sci Technol. 2019; 52: 303-315. [CrossRef]
- Radomska-Soukharev A. Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007; 59(6): 411-418. [CrossRef]
- Freitas C, Müller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int J Pharm. 1998; 168(2): 221-229. [CrossRef]
- Kumar S, Randhawa JK. Paliperidone-loaded spherical solid lipid nanoparticles. RSC Advances. 2014; 4(57): 30186- 30192. [CrossRef]
- Gaber DM., Nafee N, Abdallah OY. Myricetin solid lipid nanoparticles: Stability assurance from system preparation to site of action. Eur J Pharm Sci. 2017; 109: 569-580. [CrossRef]
- Zheng B, McClements DJ. Formulation of more efficacious curcumin delivery systems using colloid science: enhanced solubility, stability, and bioavailability. Molecules. 2020; 25(12): 2791. [CrossRef]
- Antioxidant Assay Kit Technical Bulletin, Sigma-Aldrich. Catalog number: CS0790.
- Badilli U, Tuba Sengel-Turk C, Onay-Besikci A, Tarimci N. Development of etofenamate-loaded semisolid SLN dispersions and evaluation of anti-inflammatory activity for topical application. Curr Drug Deliv. 2015; 12(2): 200- 209. [CrossRef]
- [52] Amasya G. A novel formulation strategy for skin occlusion: Semi-solid lipid nanoparticles. Journal of Research in Pharmacy (online). 2021; 25(4): 388-397. [CrossRef]
- Fang JY, Fang CL, Sung KC, Chen HY. Effect of low frequency ultrasound on the in vitro percutaneous absorption of clobetasol 17-propionate. Int J Pharm. 1999; 191: 33-42. [CrossRef]
- Billich A, Aschauer H, Aszódi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004; 269: 29-35. [CrossRef]
There are 54 citations in total.
Details
| Primary Language | English |
|---|---|
| Subjects | Pharmacology and Pharmaceutical Sciences (Other) |
| Journal Section | Articles |
| Authors | |
| Publication Date | June 27, 2025 |
| Published in Issue | Year 2023 Volume: 27 Issue: 2 |